drug_type
RELEVANT_DRUG
intervention_type
Autologous cellular therapy (TIL)
drug_description
Autologous tumor-infiltrating lymphocyte (TIL) cell therapy expanded ex vivo and infused IV after lymphodepletion to mediate tumor cell killing via TCR recognition of neoantigens.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepletion to recognize patient-specific tumor neoantigens via native TCR–MHC interactions and kill tumor cells through perforin/granzyme-mediated cytotoxicity and cytokine-driven immune activation and persistence.
drug_name
NEOG-100 (tumor-infiltrating lymphocytes)
nct_id_drug_ref
NCT06107894